Corvidia Therapeutics

Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases.

After receiving seed funding from Sofinnova Partners in 2015, our company was founded around a pipeline of assets with best in class potential to make a positive impact on patients with cardio-renal diseases. Since then, we have raised $26 million in Series A financing led by Sofinnova Partners and Apple Tree Partners and, $60 million in Series B financing led by Venrock which included Andera Partners, Cormorant Asset Management, HBM Partners and Fresenius Medical Care Ventures GmbH.

We develop the right therapy for the right patient to address significant, unmet medical needs. Our pipeline is currently focused on treating the life-threatening conditions of Chronic Kidney Disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride induced Acute Pancreatitis, both conditions that do not have an approved therapy.